Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
05 2020
Historique:
received: 18 07 2019
revised: 17 10 2019
accepted: 07 11 2019
entrez: 12 5 2020
pubmed: 12 5 2020
medline: 29 8 2020
Statut: ppublish

Résumé

To qualitatively explore patient experiences of severe, recurrent, bilateral nasal polyps (NP). A targeted literature review of published qualitative studies and online blogs describing patient experiences of NP was conducted. Semistructured concept elicitation interviews were conducted in the United States and Germany with participants ≥18 years with severe, recurrent, bilateral NP to explore their symptom experience and impacts on health-related quality of life (HRQoL; NCT03221192). A subset of 10 participants reported symptoms and impacts using a smartphone or tablet application (app) over a 10-day period. A paucity of qualitative evidence regarding patient experience of NP was identified from the literature or blog review. Twenty-seven participant interviews were conducted. Thirty-six symptoms were identified, including 7 primary symptoms (nasal congestion [n = 27 of 27], breathing difficulties [n = 27 of 27], postnasal drip [n = 25 of 27], runny nose [n = 24 of 27], head/facial pressure [n = 23 of 27], loss of smell [n = 23 of 27], loss of taste [n = 22 of 27]) and 29 secondary symptoms (the most common were mucus/catarrh and nose bleeds [both n = 20 of 27]). Most symptoms were reported to vary both within and between days. Sixty impacts of severe NP were reported, including impacts on sleep (n = 22 of 27), physical functioning (n = 21 of 27), activities of daily living (n = 21 of 27), emotional well-being (n = 27 of 27), treatment (n = 23 of 27), social life (n = 26 of 27), and work (n = 19 of 27). Symptoms/impacts reported using the app were consistent with interview findings, although new symptoms were identified (ear pain, throat pain, nasal scabs, and nasal burning). These results supported the development of a conceptual model outlining concepts related to symptoms, impacts, and treatment of NP. Severe, recurrent, bilateral NP are associated with a range of symptoms that have significant detrimental impact on HRQoL.

Identifiants

pubmed: 32389229
pii: S1098-3015(20)30050-4
doi: 10.1016/j.jval.2019.11.005
pii:
doi:

Substances chimiques

Steroids 0

Banques de données

ClinicalTrials.gov
['NCT03221192']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

632-641

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Rebecca Hall (R)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, England, UK.

Claire Trennery (C)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, England, UK.

Robert Chan (R)

Clinical Sciences, GlaxoSmithKline R&D, Stockley Park, Uxbridge, England, UK.

Adam Gater (A)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, England, UK.

Helena Bradley (H)

Patient-Centered Outcomes, Adelphi Values, Bollington, Cheshire, England, UK.

Mirko V Sikirica (MV)

Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA.

Robyn von Maltzahn (R)

Patient Centred Outcomes, Value Evidence and Outcomes, GlaxoSmithKline, London, England, UK. Electronic address: robyn.x.von-maltzahn@gsk.com.

Ana R Sousa (AR)

Clinical Sciences, GlaxoSmithKline R&D, Stockley Park, Uxbridge, England, UK.

Linda M Nelsen (LM)

Patient Centred Outcomes, Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH